胸腺肽在复治肺结核的临床疗效

Clinical efficacy of thymosin in re-treatment of tuberculosis

目的研究胸腺肽在复治涂阳肺结核的临床疗效。方法本研究纳入我院收治的70例复治涂阳肺结核患者,随机数字表法均分为两组,各35例,对照组给予2RDCO/10RDOT方案、常规抗结核治疗,观察组在对照组治疗基础上联合胸腺肽治疗。连续6个月,比较治疗3个月、6个月、12个月病灶吸收率、空洞关闭率及痰菌转阴情况,比较治疗前后免疫细胞水平,并记录不良反应发生情况。结果观察组治疗病灶吸收率、空洞关闭率及痰菌转阴率均显著高于对照组(P<0.05);两组治疗后免疫细胞水平均显著改善,且治疗后观察组多项免疫指标改善明显好于对照组;两组药物不良反应率差异无统计学意义(P>0.05)。结论胸腺肽能促进复治涂阳肺结核病灶吸收及痰菌转阴,与胸腺肽增强细胞免疫功能,纠正免疫失调有关。

Objective To study the clinical efficacy of thymosin in re-treatment of smear-positive pulmonary tuberculosis.Methods 70 cases of retreated smear-positive pulmonary tuberculosis were enrolled in this study,and they were randomly divided into two groups,35 cases in each group.The control group was given routine anti-tuberculosis treatment with 2RDCO/10RDOT regimen,while the observation group was treated with thymosin on the basis of the control group.For 6 consecutive months,the lesion absorption rate,cavity closure rate and sputum negative conversion were compared between the two groups 3 months,6 months and 12 months after treatment.The levels of T lymphocyte subsets were compared before and after treatment,and the occurrence of adverse reactions was recorded.Results The absorption rate,cavity closure rate and sputum negative conversion rate of the observation group were significantly higher than those of the control group(P<0.05).Tlymphocyte subsets of the two groups were significantly improved after treatment,and many immune indexes of the observation group were significantly better than those of the control group after treatment.There was no significant difference in adverse drug reactions between the two groups(P>0.05).Conclusion Thymosin can promote the absorption of smear-positive pulmonary tuberculosis lesions and the negative transformation of sputum bacteria,which is related to the enhancement of cellular immune function and the correction of immune imbalance by thymosin.